Home / Knowledge hub /
Webinar | A Bridge to the Future of Aseptic Manufacturing: A Pharma 4.0 Case Study
January 15, 2026
Growing demand for high-quality sterile fill finish capacity is putting pressure on development timelines and supply programs across the industry. As expectations for Annex 1 alignment, agility and data-driven control rise, partners need facilities designed to keep pace with evolving requirements.
In this on-demand webinar, Chad Hafer, Director of Technical Operations, Aseptic Fill Finish at Kindeva, walks through the thinking behind the Bridgeton sterile fill finish campus. He explains how Pharma 4.0 concepts and the Annex 1 draft informed our approach, and what that meant for building a site that can keep pace as expectations evolve.
Watch Chad’s full talk to learn more about:
- The design principles that shaped our Bridgeton facility
- The role of automation and interconnectivity across our aseptic manufacturing
- How we built in flexibility and scalability from day one
- Our approach to supporting vials, prefilled syringes and cartridges, delivering close to 100% OTIF to our customers
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Beyond the bench: Aerosol analysis and the physics of MDI performance
Modern drug delivery is built on an architecture of precision and predictability to ensure patient safety. Behind every successful inhalation therapy lies a methodical application of analytical science that characterizes the behavior of complex aerosol systems. In this Beyond the bench blog, we examine how this analytical backbone supports the development of pressurized metered-dose inhalers […]
Learn More
Powering every breath you give: Our world-class Loughborough site
Pulmonary drug delivery is undergoing a period of rapid change. Developers must bring increasingly complex therapies to market while preparing inhalers for the transition to low-Global Warming Potential (GWP) propellant technologies. Success depends on having expertise across formulation, device integration and scalable manufacturing capabilities. Kindeva’s Loughborough, UK facility stands ready for this evolution. Our global […]
Learn More
Parenteral capabilities overview
Next-generation biologics and combination products require precision and close coordination between drug delivery technologies and manufacturing execution. Kindeva advances parenteral programs across development and commercial supply by bringing together device expertise, aseptic manufacturing and scalable operations. Why choose Kindeva for your parental program Large-scale sterile fill finish The Bridgeton site supports vial, cartridge and prefilled […]
Learn More
Navigating the green revolution: Why next-generation propellants are critical for pMDIs
The imperative to address climate change is reshaping industries worldwide, and pharmaceutical manufacturers are no exception. In respiratory medicine, the spotlight has fallen on pressurized metered-dose inhalers (pMDIs). While crucial for millions of patients, pMDIs harness propellants with a global warming potential (GWP) many times higher than CO2. This significant environmental footprint is a critical […]
Learn More
Where the propellants are greener: Inside the MDI facility of the future
As the pharmaceutical industry accelerates toward net-zero goals, inhalation therapies face unique scrutiny. Pressurized metered-dose inhalers (pMDIs) remain vital for millions of patients, yet their reliance on legacy propellants presents a sustainability challenge. To address this, Kindeva has established its UK headquarters and MDI Center of Excellence in Loughborough, a facility purpose-built to lead the […]
Learn More
Career journeys blog 4: Grace Guo
In this story, we meet Grace Guo, Manager of Client Portfolio Relationship Management, whose pathway at Kindeva has grown through clear communication, strategic thinking and a strong focus on people.
Learn More
The next leap in skin-based drug delivery: How dermal delivery platforms are transforming tomorrows for patients
Skin-based drug delivery is gaining attention as patients and healthcare systems look for treatments that support at-home administration and remove the need for needle-based injections. As this shift accelerates, developers are investing in technologies that improve usability without compromising performance. These platforms are opening new possibilities for therapies that rely on reliable, patient-preferred delivery. A […]
Learn More
Career journeys blog 3: Lauren Harrison
In this story, we meet Lauren Harrison, a formulation scientist who began her path as an apprentice and has spent the last decade building a career rooted in curiosity, hands-on learning and collaboration.
Learn More
Navigating the transition to next-generation propellants for pMDIs | On-demand webinar
Regulators, health systems and patients expect meaningful progress on sustainability. For pressurized metered dose inhalers (pMDIs), this means planning the transition to low global warming potential (low-GWP) next-generation propellants (NGPs) now, not at the end of the decade. In this webinar with Pharmaceutical Technology, Craig Somerville, Senior Vice President of Kindeva’s pMDI business unit, shares […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.